

رسالة

THE PROGNOSTIC SIGNIFICANCE OF BCL2 ONCOGENE EXPRESSION IN MALIGNANT OVARIAN TUMORS

THESIS

Submitted in the Partial
Fulfillment for the Master Degree
In Obstetric & Gynaecology



BY

618-11
A. F.

Amal Fouad Abd El-Reheem

M.B., B.Ch.

Faculty of Medicine - Cairo University (1991)
Resident Registrar in Obstetrics & Gynaecology
at El-Monera General Hospital
Ministry of Health

SUPERVISED BY

Prof. Dr. Ahmed Galal El-Laithy

Professor of Obstetrics & Gynecology
Faculty of Medicine - Ain Shams University

Dr. Amro Salah El-Din El-Hoseny

Lecturer of Obstetrics & Gynecology
Faculty of Medicine - Ain Shams University

Dr. Magda Hassan Nasr El-Din

Assistant Professor of Pathology
Faculty of Medicine - Ain Shams University

Faculty of Medicine
Ain Shams University

1997

Acknowledgement

It is my pleasure that I acknowledge who deserve credit for the evolution of the present work. I am particularly grateful to my Prof. Dr. Ahmed Galal El-Laithy, who has constantly supervised and supported me, as well as for the paternal care he offered me.

I wish to acknowledge with gratitude, the help and support provided to me by Dr. Amro Salah El-Din El-Houssieny and wish to thank him for his time and effort without which I wouldn't have been able to present this work.

I wish to express my particular and profound gratitude to Dr. Magda Hassan Naser El-Deen, for her great assistance, help guidance and faithful advice throughout the work. It is honor for me to be among her students, as I have learned much from her valuable knowledge and discussion.

I wish also to express a particular & profound gratitude to Dr. Mohamed Ahmed Ibrahim Laban, who gave me the idea of that work & who started that work, he gave me valuable advices, without him, I wouldn't be able to present that work.

Last but by no means least, I thank my parents for their assistance, continuous encouragement, and love.



Dedication

To My

Family

CONTENTS

| | PAGE |
|---|------|
| <i>Introduction and Aim of the Work</i> | 1 |
| <i>Review of Literature</i> | 6 |
| <i>Structure of the Cell</i> | 6 |
| <i>Apoptosis</i> | 25 |
| <i>Ovarian Cancer</i> | 41 |
| <i>Patients and Methods</i> | 66 |
| <i>Results</i> | 74 |
| <i>Discussion</i> | 121 |
| <i>Summary and Conclusion</i> | 130 |
| <i>References</i> | 133 |
| <i>Arabic Summary</i> | |

LIST OF FIGURES

| | <i>PAGE</i> |
|--|-------------|
| Figure (1): Structure of the cell..... | 7 |
| Figure (2): Modes of delivery of growth factors | 10 |
| Figure (3): General components of signal transduction..... | 12 |
| Figure (4): The cell cycle | 14 |
| Figure (5): Mechanisms of action of oncogenes and suppressor genes in normal and cancer cells | 20 |
| Figure (6): Mechanisms by which an oncogene may promotes cell growth | 21 |
| Figure (7): Incorporation of a viral oncogene into eukaryotic DNA genome | 23 |
| Figure (8): Cancer pathogenesis | 24 |
| Figure (9): Normal tissue homeostasis..... | 36 |
| Figure (10): Reagents supplied | 70 |
| Figure (11): Hisopathological types of malignant ovarian tumours | 78 |
| Figure (12): BCL-2 expression in normal ovaries, benign and malignant tumours..... | 87 |
| Figure (13): BCL-2 expression in different pathological grades of malignant tumours..... | 91 |
| Figure (14): BCL-2 expression and age in normal controls and malignant patients..... | 93 |
| Figure (15): BCL-2 expression in patients with and without lymph nodes..... | 96 |

| | | |
|--------------|---|-----|
| Figure (16): | BCL-2 expression in different clinical stages of malignant tumours..... | 99 |
| Figure (17): | Survival in malignant patients according to BCL-2 expression..... | 104 |
| Figure (18): | Positive control slide | 110 |
| Figure (19): | Immunostaining for BCL-2 oncoprotein in psammomatous carcinoma | 111 |
| Figure (20): | Immunostaining for BCL-2 oncoprotein in squamous cell carcinoma on top of mature teratoma..... | 112 |
| Figure (21): | Higher magnification for immunostaining of BCL-2 oncoprotein in squamous cell carcinoma on top of mature teratoma | 113 |
| Figure (22): | Immunostaining for BCL-2 oncoprotein in clear cell carcinoma | 114 |
| Figure (23): | Immunostaining for BCL-2 oncoprotein in well differentiated endometroid carcinoma..... | 115 |
| Figure (24): | Immunostaining for BCL-2 oncoprotein in well differentiated papillary serous carcinoma | 116 |
| Figure (25): | Immunostaining for BCL-2 oncoprotein in granulosa cell tumour | 117 |
| Figure (26): | Immunostaining for BCL-2 oncoprotein in malignant mixed mullerian | 118 |
| Figure (27): | Immunostaining for BCL-2 oncoprotein in another case of Malignant Mixed Mullerian | 119 |
| Figure (28): | Immunostaining for BCL-2 oncoprotein in case of Krukenberg tumour | 120 |

LIST OF TABLES

| | PAGE |
|---|------|
| Table (1): Oncogene Categories..... | 39 |
| Table (2): Carcinoma of the ovary. Staging according to FIGO stage | 50 |
| Table (3): Pathology of benign ovarian tumours..... | 75 |
| Table (4): Pathology of malignant ovarian neoplasms..... | 77 |
| Table (5): Distribution, histopathological type & grade among the malignant ovarian neoplasms..... | 80 |
| Table (6): Range & mean of age among the benign and malignant ovarian neoplasm patients | 82 |
| Table (7): Reproductive state among both benign & malignant ovarian neoplasm patients | 82 |
| Table (8): Tumor stages among patients with malignant ovarian neoplasm at staging laporatomy..... | 83 |
| Table (9): The state of lymph nodes during laporatomy operations among the malignant ovarian neoplasm patients..... | 84 |
| Table (10): The results of cytoreduction operations among the malignant ovarian neoplasm patients..... | 84 |
| Table (11): The incidence and numbers of bcl- <u>2</u> oncoprotein positively among benign & malignant ovarian neoplasms | 86 |
| Table (12): The distribution of bcl-2 oncoprotein according to the histopathological subtype among patients with malignant ovarian neoplasms..... | 89 |
| Table (13): The distribution of bcl-2 oncoprotein according to the tumour grade among patients with malignant ovarian neoplasms | 90 |

| | | |
|-------------|--|-----|
| Table (14): | The relation between bcl-2 oncoprotein expression and patients' age as well as their parity | 92 |
| Table (15): | The results of chi-square test in investigating the relation between reproductive state and the distribution of bcl-2 oncoprotein among different malignant ovarian neoplasms..... | 94 |
| Table (16): | The relation between the local lymph node metastases and bcl-2 expression among patients with malignant ovarian neoplasms..... | 95 |
| Table (17): | Bcl-2 oncoprotein expression in relation to the results of cytoreduction operations..... | 97 |
| Table (18): | The distribution of bcl-2 in relation to tumour stage among patients with malignant ovarian neoplasms..... | 98 |
| Table (19): | The clinical features & Bcl-2 oncoprotein expression among patients with poor prognostic outcome | 101 |
| Table (20): | The pathological features and Bcl-2 expression among patients with poor prognostic outcome | 102 |
| Table (21): | Alive patients with favourable prognosis and those who died from their disease in bcl-2 oncoprotein expression..... | 103 |
| Table (22): | Bcl-2 expression and prognosis in patients with malignant ovarian neoplasms..... | 106 |
| Table (23): | Living patients with favourable prognosis & living patients with poor prognosis in bcl-2 oncoprotein expression..... | 107 |
| Table (24): | Bcl-2 expression and prognosis with stage III & IV malignant ovarian neoplasms..... | 108 |
| Table (25): | Bcl-2 expression and survival in patients with malignant ovarian tumours and residuals less than 2cms..... | 109 |



Introduction and Aim of the Work

Introduction

Ovarian malignancy accounts for almost 25% of gynaecological cancer, making it the fifth common malignancy in females. The disease has a very high mortality rate and account for 50% of all deaths from cancer of female genital tract. No satisfactory investigations for screening, early diagnosis has yet been established and the disease has often spread widely when first found. Ovarian cancer, without doubt, presents the greatest challenge to the gynaecological oncologist (K.R. Peel, 1995).

Treatment of ovarian cancer is aggressive primary debulking surgery followed by chemotherapy in most cases especially advanced disease. Although different clinical trials have been carried out, only a marginal increase in survival has been obtained. Our lack of basic knowledge of the tumour biology underlying this disease presents a major obstacle to improve treatment, as well as to establish treatment modalities based on aetiological and pathogenetic evidence (Henriksen et al., 1993).

Development as well as maintenance of many adult tissues is achieved by several dynamically regulated processes that include cell proliferation, differentiation, and programmed cell death (apoptosis).

Although a great deal has been learned in recent years about the regulation of cell proliferation, relatively little is known about the regulation of cell death (Ellis et al., 1991; Raff, 1992). Recently attention has begun to focus on the mechanisms that regulate programmed cell death (apoptosis) (Williams, 1991). Apoptosis is an active process by which many cells die during their development and self-maintenance in complex eukaryocytes (Kerr et al., 1972). Cell death by apoptosis occurs when a cell activates an internally encoded suicide program as a result of either extrinsic or intrinsic signals.

Apoptotic cell death is characterized by plasma membrane blebbing, cell volume loss, nuclear condensation, and endonucleolytic degradation of DNA at nucleosomal intervals (Wyllie et al., 1980).

Although apoptosis plays an important role in normal physiological situations, where it help to ensure the rate of new cell production in proliferative tissues is offset by commensurate ^{متعادله} rate of cell death, it is also important clinically because many chemotherapeutic drugs appear to ultimately kill cancer cells by activating undefined biochemical pathways leading to programmed cell death.

Some of genes involved in the regulation of the physiological cell death have been identified, among these bcl-2 gene has emerged as a key regulator of the cell death process. Bcl-2 appears to control a down-stream event in a final

common pathway leading to apoptotic cell death, and can protect cells from death induced by myriad of insults including radiation, chemotherapeutic drugs, cytotoxic lymphokines, some viruses, excitotoxic neurotransmitters and growth factor deprivation. In vivo, Bcl-2 expressed in a variety of cell types particularly long lived cells such as memory lymphocytes and some types of neurons, as well as regenerating stem cells that line the basement membrane and prostate.

The Bcl-2 (B-cell lymphoma/leukaemia 2) gene was first discovered because of its involvement in the t(14,18) chromosomal translocations found in the majority of non-Hodgkin's lymphomas. As consequence of this translocation, Bcl-2 gene from 18q21 moves into juxtaposition with powerful enhancer elements located within immunoglobulin heavy chain locus at 14Q32, thus deregulating the expression of Bcl-2 gene in these tumors of B-lymphocyte origin. The end result is the continuous production at high level of the normal Mw 26,000 of Bcl-2 protein which is the principle product of Bcl-2 gene (John C. Reed et al., 1991).

The human Bcl-2 protein is an intracellular integral membrane protein. The topic of intracellular membranes in which Bcl-2 resides. However is controversial, Recently Jacobson et al. (1993) obtained evidence from 2-color immunofocal microscopy suggesting that Bcl-2 can enter membranes of endoplasmic reticulum, nuclear envelop and mitochondria. Where

overexpressed in fibroblast like cells. In separate study involving primarily immunoelectromicroscopic methods, Monghan et al., Reported that Bcl-2 residues in nuclear envelop and outer mitochondrial membranes.

PROGNOSTIC FACTORS IN OVARIAN CARCINOMA

Histopathological type as serous tumours are said to be more aggressive than endometroid and mucinous type, tumor grade, tumor stage presence of ascites, residual tumor after surgery, new prognostic markers include DNA ploidy, S-phase Fraction, Estrogen and Progesterone receptor status, cerb B2 oncogen expression, Epidermal growth factor receptor expression and Bcl-2 oncogen expression appear to be an important prognostic factor in ovarian carcinoma.

AIM OF THE WORK

1. To study Bcl-2 expression in:
 - a) Normal ovarian tissues.
 - b) Benign ovarian neoplasms.
 - c) Malignant ovarian neoplasms.
2. Evaluate the Correlation between Bcl-2 expression in ovarian tumors and survival.